Cardiology in Review最新文献_第3页

Safety and Efficacy of Nondihydropyridine Calcium Channel Blockers for Acute Rate Control in Atrial Fibrillation with Rapid Ventricular Response and Comorbid Heart Failure with Reduced Ejection Fraction. 非二氢吡啶钙通道阻滞剂用于控制心房颤动伴快速心室反应和伴射血分数降低的心力衰竭患者的急性心率的安全性和有效性。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-03-01 Epub Date: 2023-08-07 DOI: 10.1097/CRD.0000000000000585

Paul C Montana, Phillip Rubin, Michael D Dyal, Jeffrey Goldberger

{"title":"Safety and Efficacy of Nondihydropyridine Calcium Channel Blockers for Acute Rate Control in Atrial Fibrillation with Rapid Ventricular Response and Comorbid Heart Failure with Reduced Ejection Fraction.","authors":"Paul C Montana, Phillip Rubin, Michael D Dyal, Jeffrey Goldberger","doi":"10.1097/CRD.0000000000000585","DOIUrl":"10.1097/CRD.0000000000000585","url":null,"abstract":"The use of nondihydropyridine calcium channel blockers (NDCCBs) to achieve rate control in atrial fibrillation with the rapid ventricular rate (AF RVR) is not recommended in patients with comorbid heart failure with reduced ejection fraction (HFrEF) due to the concern for further blunting of contractility. However, these recommendations are extrapolated from data examining chronic NDCCB use in HFrEF patients, and comorbid AF was not analyzed. These recommendations also do not cite the hemodynamic effects or clinical outcomes of NDCCBs for acute rate control in HFrEF patients with AF RVR. It is our goal to open the discussion concerning the hemodynamic effects and safety profile of NDCCBs for acute rate control in this specific patient population. In the acute setting of AF RVR and HFrEF, there is a paucity of low-quality data on the safety and hemodynamic effects of NDCCBs, with mixed results. There has not been a clear signal toward adverse outcomes with NDCCBs, particularly for diltiazem. Data in this scenario is similarly limited for beta blockers, which provide the additional hemodynamic effect of the neurohormonal blockade, which provides a long-term mortality benefit to HFrEF patients. We support the cautious use of beta blockers as first-line therapy in clinical settings where an acute rate control strategy for AF RVR is warranted. We also support diltiazem as a reasonable second-line option, though the relative paucity of data calls for further research to validate this conclusion. Verapamil in this setting should be avoided until more data are available.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"129-134"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9937961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of Hypoplastic Left Heart Genotypes and Phenotypes; The Window toward Future Cell-Based Therapy: A Narrative Review.

IF 2 4区医学

Cardiology in Review Pub Date : 2025-02-28 DOI: 10.1097/CRD.0000000000000878

Mohsen Shahidi

{"title":"Identification of Hypoplastic Left Heart Genotypes and Phenotypes; The Window toward Future Cell-Based Therapy: A Narrative Review.","authors":"Mohsen Shahidi","doi":"10.1097/CRD.0000000000000878","DOIUrl":"https://doi.org/10.1097/CRD.0000000000000878","url":null,"abstract":"Hypoplastic left heart syndrome (HLHS) is a prevalent and lethal type of single ventricle anomaly. During early prenatal evaluations, left heart hypoplasia may be neglected due to its progressive features. It is a heterogeneous congenital heart disease with different phenotypes. Currently, there is no definite treatment for HLHS. This is in part due to its heterogeneous phenotypes that require different management. In addition, hindrances in recognizing the etiologic factors do not allow early preventive or therapeutic procedures. Phenotypic determination is fundamental to identifying the etiologic factors and therapeutic strategies. This review article introduces comprehensive information about different phenotypes and genotypes of HLHS and their novel molecular strategy. Genetic defects and flow-mediated mechanisms are the main known factors of HLHS. Recent studies reported additional data about its nonmendelian genetic origins associated with heterogeneous phenotypes. The genetic defects influence endocardium or cardiomyocyte development to yield early or late valve deformities and myocardial malformations. The new molecular therapeutic methods are essentially based on genetic etiologies. The principal therapeutic purpose is reinforcing the function of the right ventricle in patients with nonfunctional left ventricles. The ultimate desire is to create a biventricular heart in selected cases.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atrial Fibrillation and Stable Coronary Artery Disease: Time to rethink the standard of care?

IF 2 4区医学

Cardiology in Review Pub Date : 2025-02-28 DOI: 10.1097/CRD.0000000000000882

Muhammad Adnan Zaman, Muhammad Imtiaz

引用次数: 0

Hypertensive Disorders of Pregnancy: A Review of the Current Literature and Future Directions.

IF 2 4区医学

Cardiology in Review Pub Date : 2025-02-27 DOI: 10.1097/CRD.0000000000000870

Juhi Ramchandani, Jasmine Garg, Geetha Rajendran, Wilbert S Aronow, William H Frishman, Chhaya Aggarwal Gupta

引用次数: 0

Comparative Efficacy of Mechanical Versus Manual Compression Techniques on Radial Artery Hemostasis Following Transradial Coronary Angiography: A Meta-Analysis.

IF 2 4区医学

Cardiology in Review Pub Date : 2025-02-27 DOI: 10.1097/CRD.0000000000000866

Hritvik Jain, Maryam Shahzad, Nandan Patel, Jyoti Jain, Ramez M Odat, Raheel Ahmed, Surender Deora

{"title":"Comparative Efficacy of Mechanical Versus Manual Compression Techniques on Radial Artery Hemostasis Following Transradial Coronary Angiography: A Meta-Analysis.","authors":"Hritvik Jain, Maryam Shahzad, Nandan Patel, Jyoti Jain, Ramez M Odat, Raheel Ahmed, Surender Deora","doi":"10.1097/CRD.0000000000000866","DOIUrl":"https://doi.org/10.1097/CRD.0000000000000866","url":null,"abstract":"Mechanical compression for hemostasis posttransradial coronary angiography (CAG) or intervention is hypothesized to be more effective than manual compression owing to a more stable and continuous pressure. However, the current evidence comparing these 2 compression techniques is limited. A comprehensive search of the 3 major electronic databases-PubMed, Google Scholar, and Cochrane Library-was performed from inception to October 24, 2024, to identify relevant studies. Standardized mean difference and risk ratios (RR) with 95% confidence intervals (CIs) were pooled using the Mantel-Haenszel random effects model to calculate effect estimates. Statistical significance was set at P < 0.05. Four studies with 1235 patients undergoing transradial CAG were included [mechanical (n = 450) and manual (n = 785)]. On pooled analysis, the mechanical compression method demonstrated a significantly longer mean time to achieve hemostasis (standardized mean difference: 3.21; 95% CI: 1.71, 4.71; P < 0.0001) than the manual compression method. The risks of radial artery occlusion (RR: 1.05; 95% CI: 0.50, 2.22; P = 0.89), hematoma formation (RR: 1.86; 95% CI: 0.28, 12.40; P = 0.52), and bleeding during compression (RR: 0.23; 95% CI: 0.00, 24.81; P = 0.54) were comparable. Both types of hemostatic compression, manual and mechanical, are equally effective though mechanical compression takes significantly longer to achieve hemostasis. Further prospective randomized studies are needed to corroborate these findings.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Renal Denervation: A New Therapy for Resistant Hypertension.

IF 2 4区医学

Cardiology in Review Pub Date : 2025-02-27 DOI: 10.1097/CRD.0000000000000860

Dhaval B Trivedi, Manish A Parikh, Gioia Turitto, William H Frishman, Stephen J Peterson

{"title":"Renal Denervation: A New Therapy for Resistant Hypertension.","authors":"Dhaval B Trivedi, Manish A Parikh, Gioia Turitto, William H Frishman, Stephen J Peterson","doi":"10.1097/CRD.0000000000000860","DOIUrl":"https://doi.org/10.1097/CRD.0000000000000860","url":null,"abstract":"The Food and Drug Administration (FDA) recently approved renal denervation to treat resistant hypertension. This procedure is a minimally invasive procedure that starts by placing a catheter in the renal artery. This catheter is used to send either radiofrequency heat or ultrasound waves to burn the superficial nerves surrounding the renal arteries while making certain no damage happens to the renal arteries themselves. This procedure is done after a renal angiogram to ensure patency of the renal artery. Each radiofrequency ablation will take 1-2 minutes, depending on the device used. The radiofrequency balloon generator requires one single application of the radiofrequency pulse. The radiofrequency generator that uses a catheter tube will need more than one pulse. The second approved option uses ultrasound to generate an electrical signal that is converted into ultrasound vibration, that occurs at the distal end of the catheter. This vibration heats the system around the nerves, disrupting the superficial nerves that communicate with the central nervous system. This will result in lowering the blood pressure. We will review the studies that led to FDA approval, and the current guidelines for use. The FDA now approves both devices.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updated Review of Transcatheter Strategies and Intervention for Mitral Regurgitation.

IF 2 4区医学

Cardiology in Review Pub Date : 2025-02-27 DOI: 10.1097/CRD.0000000000000876

Siddhant Passey, Haris Patail, Daniel Spevack, Hasan Ahmad, Suguru Ohira, Junichi Shimamura, William H Frishman, Wilbert S Aronow, Syed Abbas Haidry

{"title":"Updated Review of Transcatheter Strategies and Intervention for Mitral Regurgitation.","authors":"Siddhant Passey, Haris Patail, Daniel Spevack, Hasan Ahmad, Suguru Ohira, Junichi Shimamura, William H Frishman, Wilbert S Aronow, Syed Abbas Haidry","doi":"10.1097/CRD.0000000000000876","DOIUrl":"https://doi.org/10.1097/CRD.0000000000000876","url":null,"abstract":"Mitral regurgitation (MR) is a prevalent valvular heart disease with significant morbidity, particularly in aging populations. Management strategies for MR have evolved from traditional open-heart surgery to innovative transcatheter approaches, addressing the limitations of surgical repair in high-risk patients. Transcatheter edge-to-edge repair, exemplified by devices such as MitraClip and PASCAL, has shown efficacy in reducing MR severity, improving functional capacity, and decreasing heart failure hospitalizations in selected patients. Advances in annuloplasty and chordal repair offer minimally invasive options with promising early outcomes. Transcatheter mitral valve replacement represents the frontier of MR treatment, addressing anatomical complexities unsuitable for repair, though complications such as left ventricular outflow tract obstruction persist. Emerging data from clinical trials underscore the importance of patient selection and a multidisciplinary heart team approach. In this review, each modality is discussed concerning its indications, procedural techniques, outcomes, and associated challenges. It highlights the transformative potential of transcatheter mitral valve interventions while emphasizing the need for ongoing innovation and research to optimize outcomes and expand therapeutic options for patients with severe MR.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tadalafil Use in Cardiovascular Disease.

IF 2 4区医学

Cardiology in Review Pub Date : 2025-02-27 DOI: 10.1097/CRD.0000000000000877

Mohammed Kallash, William H Frishman

{"title":"Tadalafil Use in Cardiovascular Disease.","authors":"Mohammed Kallash, William H Frishman","doi":"10.1097/CRD.0000000000000877","DOIUrl":"https://doi.org/10.1097/CRD.0000000000000877","url":null,"abstract":"Tadalafil is a phosphodiesterase inhibitor currently approved for use in erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). While tadalafil's benefits in ED and BPH have been well-established for years, its benefits in PAH were identified only recently in major clinical trials, resulting in the recent approval of a single-tablet, combination therapy of tadalafil with an endothelin receptor antagonist for PAH. With Tadalafil's cardiovascular benefits in ED, BPH, and PAH, clinical researchers have begun investigating whether tadalafil's use extends to other cardiovascular diseases, especially heart failure (HF), an emerging epidemic in medicine. Recent research in animal models has demonstrated a potential benefit of tadalafil use in ischemic cardiomyopathy and HF, as numerous studies in mice and sheep demonstrated improved left ventricular function and contractility, with reduced adverse remodeling and hypertrophy. A retrospective cohort study identified that tadalafil use in patients with ED and coronary artery disease was associated with a significant decrease in the incidence of HF, acute myocardial infarction, and mortality compared with sildenafil or no treatment. However, a randomized controlled trial in patients with comorbid PAH and HF with preserved ejection fraction demonstrated no significant benefit with the use of tadalafil. Unfortunately, there is limited evidence from clinical trials investigating the impact of tadalafil in patients with HF with reduced or preserved ejection fraction without comorbid PAH. Further studies are needed on this topic to better identify whether tadalafil has a role in the prevention or treatment of HF.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The History of Angina and Its Remedies: COURAGE, ORBITA, and a Path Forward.

IF 2 4区医学

Cardiology in Review Pub Date : 2025-02-27 DOI: 10.1097/CRD.0000000000000864

Christopher Dasaro, John Mandrola, Venkatesh Murthy, Vinay Prasad

{"title":"The History of Angina and Its Remedies: COURAGE, ORBITA, and a Path Forward.","authors":"Christopher Dasaro, John Mandrola, Venkatesh Murthy, Vinay Prasad","doi":"10.1097/CRD.0000000000000864","DOIUrl":"https://doi.org/10.1097/CRD.0000000000000864","url":null,"abstract":"The recent publication of the second Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina trial has renewed debate surrounding the indications and benefits of percutaneous coronary intervention (PCI) in stable angina. The second Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina results show that PCI improves anginal symptoms in the absence of antianginal medications. Taken together with the first Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina and Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation trial results, proponents argue that in contrast to current guidance, PCI and aggressive medical therapy are both equally acceptable initial antianginal strategies and subject to patient preference. Drawing on the history of randomized studies of interventional management for stable angina, we detail our reservations with this interpretation. More broadly, we highlight the merits of elegantly designed sham-controlled trials in answering lingering clinical questions. Finally, we offer select frameworks for more conclusive trials designed to answer the looming question that cardiologists face: does the landscape of randomized evidence support a medication-first, PCI-first, or shared decision-making treatment paradigm in stable angina?","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating Pregnancy in Congenital Heart Disease: A Comprehensive Review of Maternal Outcomes.

IF 2 4区医学

Cardiology in Review Pub Date : 2025-02-25 DOI: 10.1097/CRD.0000000000000884

Rimsha Ahmad, William H Frishman, Wilbert S Aronow

引用次数: 0